Physician profile
Roxanne Marshall
NPI 1578523585
$7,193.90
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,532 · 2020: $2,208 · 2021: $1,798 · 2022: $677 · 2023: $584 · 2024: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $979.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $846.82 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Astellas Pharma US INC | $724.47 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $641.37 | 2019-2022 | |
| Abbvie INC. | $612.70 | 2021-2024 | |
| Glaxosmithkline, LLC. | $605.46 | 2020-2024 | Trelegy Ellipta |
| Novo Nordisk INC | $559.41 | 2019-2023 | Rybelsus, Ozempic |
| Pfizer INC. | $555.88 | 2019-2022 | |
| Lilly USA, LLC | $310.67 | 2020-2024 | Zepbound, Mounjaro |
| Sanofi-Aventis U.S. LLC | $227.17 | 2019-2022 | |
| Allergan, INC. | $212.75 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $210.88 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $166.91 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $140.10 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.24 | 2019-2022 | |
| Abbott Laboratories | $132.98 | 2021-2024 | Freestyle Libre |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roxanne Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.